Kinase Chemistry – Just a year and a half behind the times.


Posted by kinasepro on July 18, 2007

Pfizer’s Jak3 inhibitor CP-690,550 was described earlier listed as Ph ii-iii. For some reason that was changed, and all of its furthest advanced trials are Phase 2.

One Response to “Correction”

  1. weirdo said

    These are only current trials, and it looks like for alternate indications. If anything, this seems to be signalling the health of this molecule. Lots of Phase 2’s cost lots of money.

    The phase of development for a drug cannnot be disentangled from its indication. Pretty common for something to be in Ph. 3 for one indication, Ph. 2a for another, already approved for a third.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: